Dona Ferentes
Pengurus pengatur
- Joined
- 11 January 2016
- Posts
- 16,520
- Reactions
- 22,532
My turn to give you medical advice after your recommendation to go and contact rotten former PM Julia organisation for psychiatry checkup...For 6 months I've been using allulose, or a combo of allulose and monk fruit as a coffee sweetner.
It's said to behave as a mild GLP-1 agonist and has little or no effects on blood glucose or insulin?
I haven't noticed any weight loss but might have lower food cravings that I can ascribe to it - not sure.
Main reason I use it is to combat 'metabolic syndrome' - i.e for blood glucose and insulin control.
Taste-wise it's closer to sugar than anything else I've tried. I get it shipped from iHerb.
Yes, I’m Excited about Allulose - David Perlmutter M.D.
Allulose, a rare sugar, has gained significant attention in recent years due to its numerous health benefits, primarily concerning metabolic health. To be sure, it seems like it is everywhere …drperlmutter.com Is Allulose Safe?
Allulose has gained popularity as an artificial sweetener that tastes more like real sugar. But it may merit caution. Experts explain.health.clevelandclinic.org
Yacon will grow in your areaYacon eh? Will check it out. I'm in northern rivers NSW, so I suspect I would need a processed form that I can buy on iHerb.
I have self diagnosed metabolic syndrome or possibly diabetes. I've never gone to a medico to get a diagnosis. I do what I can at home, including almost giving up alcohol, losing some weight more activity, no added table sugar and lots of supplements.
Just joking about Beyond Blue in case it was obscure.
- hey pal, I'm calling you a fraud.Barb Stuckey, the company’s chief innovation and marketing officer, who describes herself as a hypertaster and whose tongue can detect changes in barometric pressure..
Undoubtedly Garpal but prolonging 'health span' is the word (two words).Eat, drink and be merry for tomorrow we die.
Interesting but all the other extra bonus from snoring to heart attack imho are just benefit of weight loss.It’s not just obesity. Drugs like Ozempic will change the world.
The Economist
02 Jan 2025
Every day seems to bring more exciting news. First, the drugs tackled diabetes. Then, with just an injection a week, they took on obesity. Now, they are being found to treat cardiovascular and kidney disease, and are being tested for Alzheimer’s and addiction.
It is early days yet, but glp-1 receptor agonists have all the makings of one of the most successful classes of drugs in history. As they become cheaper and easier to use, they promise to dramatically improve the lives of more than a billion people – with profound consequences for industry, the economy and society.
In the three years since semaglutide was approved for treating obesity, it has taken America by storm. After decades of disappointing “miracle cures”, these drugs work.
Image-conscious influencers and well-heeled financiers are not their only users. Already one in eight American adults has been on glp-1 drugs. Novo Nordisk, maker of semaglutide, branded Ozempic for diabetes and Wegovy for weight loss, and Eli Lilly, which makes tirzepatide, a more effective alternative, have together added about $US1 trillion ($1.5 trillion) in market value since 2021.
The action is now moving beyond America. With over two-fifths of the world overweight or obese, demand for glp-1 drugs is voracious. Pharma companies are racing to make them work as pills, which would be cheaper to produce than jabs, and to reduce their side effects.
Generic versions for older GLP-1 agonists are entering the market. Semaglutide is to come off patent in Brazil, China and India in 2026; eight such drugs are in the works in China. That is just as well. As incomes in the developing world have risen and life has become more sedentary, people’s waistlines are catching up with those in the West.
Not just curbing obesity
Curbing obesity would be consequential. Yet glp-1 drugs promise to do much more. Overweight patients on semaglutide have been found to suffer fewer heart attacks and strokes; the benefits, astonishingly, seem to be largely independent of how much weight is lost.
Tirzepatide improves sleep apnoea. Trials show that glp-1 agonists reduce chronic kidney disease in diabetics, and there are signs they may lessen brain shrinkage and cognitive decline in Alzheimer’s. Studies of health records suggest that they may help with addictions, too; people already on glp-1 drugs in America were less likely to overdose on opioids or abuse cannabis or alcohol. Researchers are even talking, in hushed tones, about their anti-ageing effects.
These drugs act in the gut, but they also bind to receptors all over the body and in the brain. They appear to reduce inflammation and interact with mechanisms linked to cravings and feelings of reward. With every new finding, researchers are learning more about the workings of disease and the links between the body and the brain.
Naturally, more work is needed. Although glp-1 agonists have been used in diabetes for 20 years, some of the newer findings are based on observational studies and will need to be supplemented by randomised trials. Patients may need to remain on these medicines for their whole lives, and their long-term benefits have yet to be quantified.
That makes the costs uncertain, too. For now, the drugs are expensive: tirzepatide is priced at over $US500 a month in America. Their immediate side effects, which can include nausea, pancreatitis, diarrhoea and muscle loss, may be off-putting; the effects from decades of taking them are uncertain. Some worry about the medicalisation of everyday life, and whether people will binge, knowing they can fall back on a cure.
Possibilities are thrilling
Yet with time, experimentation and innovation, the benefits will become clearer, and the costs will come down. Healthy habits and good public health advice will still matter.
But practitioners have long despaired that nothing works for many obese people. If the drugs live up to their early promise, it would be perverse and cruel to deprive patients of medicines that could dramatically improve their lives. The drugs could hold the same promise for addiction.
Stand back and the possibilities are thrilling. In 2019 heart disease, stroke, diabetes, Alzheimer’s and kidney disease ranked among the top ten global causes of death. By 2050, as the world ages and developing countries’ health care improves, these diseases will take a bigger toll.
For patients, the new uses of glp-1 drugs would mean not just longer, healthier and more productive lives, but happier ones, too. In a world of abundance people succumb to their impulses even if they know their behaviour is harmful in the long term. Although glp-1 agonists may limit the pleasure of instant gratification, they promise to end intrusive cravings and improve long-term health.
The total bill for prescribing these drugs could be vast. Yet for governments, they would lower some other costs including medical bills for obesity and the burden substance abuse puts on the criminal-justice system. The state would raise less revenue from taxes on alcohol, but income-tax revenues would go up, as the workforce became healthier.
As the contraceptive pill encouraged women to stay in education and work, glp-1 drugs could lead to profound economic and social change by enhancing productivity and freedom.
Some business models could be upended. If cravings can be controlled, junk-food companies, advertisers and even drug dealers may shift their focus from quantity to quality.
Social norms could evolve. In the West thinness is prized as the ideal of beauty, because for so many it is hard-won, whereas obese people suffer discrimination and lower wages. If being thin is easier, that may change. Obesity and addiction may less often be seen as moral failings, but as illnesses that can be treated. The glp-1 revolution is just beginning. Its promise is tantalising.
I hope this was not ironyAm in agreement there QF; too many "easy solutions" available
cricket not tennis (straight bat not spin)I hope this was not irony
There is no "free meal" with medication, we tweak the metabolism to compensate for an existing excess and so it is nearly a given we will alter the balance.
With side effects
We just do not know it yet
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?